Skip to main content
placeholder image

Updated interim analysis (IA) of COU-AA-302, a randomized phase III study of abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy.

Journal Article


Abstract


UOW Authors


  •   De Souza, Paul (external author)

Publication Date


  • 2013

Citation


  • Rathkopf, D. E., Smith, M. R., De Bono, J. S., Logothetis, C., Shore, N. D., De Souza, P. L., . . . Ryan, C. J. (2013). Updated interim analysis (IA) of COU-AA-302, a randomized phase III study of abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy.. Journal of Clinical Oncology, 31(6_suppl), 5. doi:10.1200/jco.2013.31.6_suppl.5

Web Of Science Accession Number


Start Page


  • 5

End Page


  • 5

Volume


  • 31

Issue


  • 6_suppl

Place Of Publication


Abstract


UOW Authors


  •   De Souza, Paul (external author)

Publication Date


  • 2013

Citation


  • Rathkopf, D. E., Smith, M. R., De Bono, J. S., Logothetis, C., Shore, N. D., De Souza, P. L., . . . Ryan, C. J. (2013). Updated interim analysis (IA) of COU-AA-302, a randomized phase III study of abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy.. Journal of Clinical Oncology, 31(6_suppl), 5. doi:10.1200/jco.2013.31.6_suppl.5

Web Of Science Accession Number


Start Page


  • 5

End Page


  • 5

Volume


  • 31

Issue


  • 6_suppl

Place Of Publication